Establishing a platform for developing and manufacturing therapeutic proteins that ensures predictable productivity and product quality will eliminate bottlenecks in tech transfer.
In this case study, Celltheon demonstrates a workflow using the Celltheon SMART Technology Platform in combination with the Allegro™ STR bioreactor range. The time from cDNA to RCB was reduced to less than 4 months while ensuring scalability between 3L to 200L pilot scale, with a pre-defined upstream and downstream processing platform for monoclonal antibodies and difficult to express proteins.
Participants will learn about:
- Improvements in current mammalian expression platforms
- Cell line development and scalability workflows
- Key features and advantages of using the Allegro STR bioreactors